Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2018 | Avoiding chemotherapy in the treatment of breast cancer

Peter Fasching • 1 Jun 2018
ASCO 2018
Breast Cancer Letrozole Ribociclib

Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Peter Fasching, MD, from University Hospital Erlangen, Erlangen, Germany, comments on the importance of the development of therapies that can overcome resistance to hormone therapy, so that the use of chemotherapy for the treatment of breast cancer can be minimized.

More from Peter Fasching

1:40
Early RIBECCA results: ribociclib with letrozole for metastatic breast cancer
Peter Fasching • 1 Jun 2018

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals